KEY TAKEAWAYSNovo Nordisk's experimental weight loss treatment amcryetin reportedly shows promising results in a Phase I trial.Early results suggest that it may be more effective than the highly popular Wegovy.The Phase II trial of the drug will be launched in the second half of 2024, with results expected in early 2026.Novo Nordisk's shares jumped to a new record high and were up more than 8% in early trading Thursday in New York. The American depositary receipts (ADRs) of Novo Nordisk A/S (NVO) gained mor ...

ToplineNovo Nordisk is now worth more than Elon Musk’s electric vehicle giant Tesla, after shares of the Danish maker of Ozempic surged following the release of promising results for an oral weight loss treatment.Elon Musk, Wegovy user and Tesla CEO.Getty Images for The New York Times Key FactsNovo Nordisk’s market capitalization surged Thursday to almost $610 billion after its stock gained 9% to a record high, after the pharmaceutical firm shared that participants in a trial for an experimental amycretin p ...

Novo Nordisk (NYSE:NVO) stock is soaring higher on Thursday after the pharmaceutical company announced results from a weight loss drug clinical trial.The big news here is the company’s oral weight loss drug amycretin producing 13.1% weight loss in patients after 12 weeks. That’s a major improvement over the 6% weight loss produced by the company’s own injectable drug Wegovy.Following this success, Novo Nordisk has announced plans for a Phase 2 clinical trial of amycretin. The company intends to start this t ...

Novo Nordisk (NYSE:NVO) unveiled a potential game changer during its Capital Markets Day with data on experimental obesity pill amycredtin potentially outperforming its blockbuster drug Wegovy. An early-stage test conducted over 12 weeks showed patients taking the pill lost 13% of their weight. Though trials are still in their early stages, Novo Nordisk (NYSE:NVO) hopes it can add another killer app to its portfolio of weight-loss drugs. The successes of Wegovy and Novo Nordisk’s other injection-based obesi ...

ToplineShares of Danish pharma giant Novo Nordisk soared to a record high on Thursday after it reported promising data on a new weight loss pill, a sign of the company’s plans to cement its prime position in the burgeoning obesity drug market in the face of stiff competition from industry titans like Eli Lilly and an array of smaller biotech startups.Early data on the pill suggested it may outperform Wegovy, an injectable prescription weight loss ... [+] medicine.UCG/Universal Images Group via Getty Images ...

Novo Nordisk (NVO) announced top-line data from the kidney outcomes study, FLOW, evaluating the efficacy of Ozempic (semaglutide) as an adjunct to standard of carefor the prevention of the progression of renal impairment in people with type II diabetes (T2D) and chronic kidney disease (CKD) compared with placebo.Per the data readout, the FLOW outcomes study achieved its primary endpoint of a superior reduction of 24% in kidney disease progression, as well as cardiovascular and kidney death for people treate ...

High-flying healthcare stock Novo Nordisk (NVO -2.58%) lost a bit of altitude on Tuesday, following its latest news from the laboratory. A clinical trial wasn't quite as successful as hoped, and investors expressed their displeasure by trading out of the Danish company's shares. At the end of the day, the stock had lost nearly 3% of its value, comparing unfavorably to the 1% decline of the benchmark S&P 500 index.A clinical trial fell short of expectationsNovo Nordisk is busy developing semaglutide, sold un ...

The weight loss drug market has been one of the most talked-about investing trends over the past year. One of the leaders in this area is Denmark-based Novo Nordisk (NVO -2.49%), thanks to its type 2 diabetes medicine Ozempic and the Wegovy version approved for weight loss. However, Ozempic and Wegovy are facing stiff competition, notably from Mounjaro and Zepbound, marketed by Novo Nordisk's eternal rival, Eli Lilly. Further, a little-known but highly promising biotech is also looking to challenge Novo Nor ...

Novo Nordisk (NYSE:NVO) said diabetes patients have been able to prevent the onset of chronic kidney disease in trials of semaglutide, which it sells under the Ozempic and Wegovy brands. The Danish drug giant hailed the headline results from its FLOW trial which reduced kidney disease progression, major adverse cardiovascular events and death by 24% compared to placebo. Around 40% of people with type 2 diabetes have chronic kidney disease. It stopped the trials on 3,533 people a full year before it was mean ...

This picture taken on October 23, 2023, shows Ozempic medication boxes, an injectable antidiabetic drug, in a pharmacy in Riedisheim, eastern France.Novo Nordisk's blockbuster drug Ozempic cut the risk of kidney disease progression and related health complications in diabetic patients, according to initial late-stage trial results released Tuesday. Ozempic specifically lowered the risk of kidney disease progression, major cardiac events and death by 24% in diabetic patients with chronic kidney disease compa ...